T-cell replete cord vs comparator relapse risk. (A) The 2-year cumulative incidence of relapse for flow MRD-positive patients was 66.2% for T-replete cord recipients compared with 36.2% for other donors (HR, 0.46 [95% CI, 0.26-0.80]; P = .007). (B) In MRD-negative patients a similar trend was seen with 2-year cumulative incidence of relapse of 8.9% for T-replete cord patients and 23.3% for the comparator group (HR, 0.36 [95% CI, 0.13-0.94]; P = .049), P-value for interaction: P = .67.